- Xigris worked, so why did Lilly withdraw the drug?
- Five years, two products: is the EU's advanced therapies legislation working?
- FDA ODAC refuses to back AVEO RCC drug tivozanib
- Genzyme's MACI to become first EU-wide approved combined ATMP
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.